Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CDK4/6 Inhibitor”

235 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 235 results

Post-approval studies (Phase 4)Ended earlyNCT04031885
What this trial is testing

Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 4
Testing effectiveness (Phase 2)UnknownNCT04318223
What this trial is testing

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer
Consorzio Oncotech 168
Testing effectiveness (Phase 2)Looking for participantsNCT04750928
What this trial is testing

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Who this might be right for
Neurofibromatosis 1
National Cancer Institute (NCI) 55
Large-scale testing (Phase 3)Active Not RecruitingNCT06764186
What this trial is testing

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
AstraZeneca 101
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Active Not RecruitingNCT01723774
What this trial is testing

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 84
Early research (Phase 1)Study completedNCT01394016
What this trial is testing

LY2835219 In Participants With Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 225
Not applicableLooking for participantsNCT06590506
What this trial is testing

High Definition Medicine for Solid Tumors Oncology

Who this might be right for
Metastatic Solid TumorAdvanced Cancer
Centro Nacional de Investigaciones Oncologicas CARLOS III 300
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Testing effectiveness (Phase 2)Study completedNCT03981614
What this trial is testing

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Who this might be right for
Metastatic Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8+3 more
Academic and Community Cancer Research United 102
Testing effectiveness (Phase 2)Ended earlyNCT01777776
What this trial is testing

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Who this might be right for
Locally Advanced Metastatic BRAF Mutant Melanoma
Array BioPharma 28
Early research (Phase 1)Study completedNCT03237390
What this trial is testing

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
Mayo Clinic 43
Testing effectiveness (Phase 2)Study completedNCT03455829
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
G1 Therapeutics, Inc. 30
Testing effectiveness (Phase 2)Study completedNCT01291017
What this trial is testing

Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.

Who this might be right for
Non-small Cell Lung Cancer
University of Florida 19
Early research (Phase 1)Ended earlyNCT04000529
What this trial is testing

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Who this might be right for
Non-small Cell Lung CarcinomaHead and Neck Squamous Cell CarcinomaEsophageal SCC+2 more
Novartis Pharmaceuticals 122
Early research (Phase 1)Ended earlyNCT02414724
What this trial is testing

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
LymphomaSolid Neoplasm
Roswell Park Cancer Institute 10
Not applicableLooking for participantsNCT06197581
What this trial is testing

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Who this might be right for
Breast Cancer, Familial MaleRadiotherapy; ComplicationsChemotherapeutic Toxicity+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 148
Testing effectiveness (Phase 2)UnknownNCT03913234
What this trial is testing

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Who this might be right for
HER2-positive Breast CancerPostmenopausalMetastatic Breast Cancer
Yonsei University 95
Large-scale testing (Phase 3)Looking for participantsNCT05861830
What this trial is testing

Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

Who this might be right for
Advanced Breast Cancer
Peking Union Medical College Hospital 80
Testing effectiveness (Phase 2)Study completedNCT02549430
What this trial is testing

To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

Who this might be right for
Breast Cancer
Fondazione Sandro Pitigliani 115
Load More Results